Logicbio Therapeutics (LOGC) Gets a Buy Rating from Chardan Capital
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Logicbio Therapeutics (LOGC), with a price target of $20.00. The company’s shares closed last Tuesday at $6.10.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 78.0% and a 71.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
Logicbio Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.00.
See today’s analyst top recommended stocks >>
Logicbio Therapeutics’ market cap is currently $184.8M and has a P/E ratio of -4.50. The company has a Price to Book ratio of 3.01.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.